Reports of Radiotherapy and Oncology

Published by: Kowsar

Pathological Diagnostic Pitfalls in the Verification of Brain Tumors; Can Imaging Lead to Pathology Alternation?

Kazem Anvari 1 , Gholamreza Bahadorkhan 2 , Fariborz Samini 2 , Payam Izadpanahi 3 , Narges Bayatmokhtari 4 and Seyed Alireza Javadinia 5 , *
Authors Information
1 Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, IR Iran
2 Shahid Kamyab Hospital, Mashhad University of Medical Sciences, Mashhad, IR Iran
3 Faculty of medicine, Birjand University of Medical Sciences, Mashhad, IR Iran
4 Reza Radiation Oncology Center, Mashhad, IR Iran
5 Student Research Committee, Department of Radiation Oncology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, IR Iran
Article information
  • Reports of Radiotherapy and Oncology: December 2015, 2 (4); e10598
  • Published Online: December 31, 2015
  • Article Type: Research Article
  • Received: November 19, 2015
  • Revised: December 1, 2015
  • Accepted: December 21, 2015
  • DOI: 10.5812/rro.10598

To Cite: Anvari K, Bahadorkhan G, Samini F, Izadpanahi P, Bayatmokhtari N, et al. Pathological Diagnostic Pitfalls in the Verification of Brain Tumors; Can Imaging Lead to Pathology Alternation?, Rep Radiother Oncol. 2015 ;2(4):e10598. doi: 10.5812/rro.10598.

Abstract
Copyright: Copyright © 2015, Reports of Radiotherapy and Oncology. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
Footnotes
References
  • 1. Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014; 16 Suppl 4-63[DOI][PubMed]
  • 2. Jazayeri SB, Rahimi-Movaghar V, Shokraneh F, Saadat S, Ramezani R. Epidemiology of primary CNS tumors in Iran: a systematic review. Asian Pac J Cancer Prev. 2013; 14(6): 3979-85[PubMed]
  • 3. Gondi V, Vogelbaum MA, Grimm S, Metha MP. Perez & Brady's Principles and Practice of Radiation Oncology. 2013; : 649-76
  • 4. Osborn AG, Salzman KL, Jhaveri MD, Barkovich AJ. Diagnostic Imaging: Brain E-Book. 2015;
  • 5. Omuro AM, Leite CC, Mokhtari K, Delattre JY. Pitfalls in the diagnosis of brain tumours. Lancet Neurol. 2006; 5(11): 937-48[DOI][PubMed]
  • 6. Chandrasoma PT, Smith MM, Apuzzo ML. Stereotactic biopsy in the diagnosis of brain masses: comparison of results of biopsy and resected surgical specimen. Neurosurgery. 1989; 24(2): 160-5[PubMed]
  • 7. Jackson RJ, Fuller GN, Abi-Said D, Lang FF, Gokaslan ZL, Shi WM, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro Oncol. 2001; 3(3): 193-200[PubMed]
  • 8. Scott CB, Nelson JS, Farnan NC, Curran WJ, Murray KJ, Fischbach AJ, et al. Central pathology review in clinical trials for patients with malignant glioma. A Report of Radiation Therapy Oncology Group 83-02. Cancer. 1995; 76(2): 307-13[PubMed]
  • 9. Hildebrand J, Gorlia T, Kros JM, Afra D, Frenay M, Omuro A, et al. Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882). Eur J Cancer. 2008; 44(9): 1210-6[DOI][PubMed]
  • 10. van den Bent MJ. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective. Acta Neuropathol. 2010; 120(3): 297-304[DOI][PubMed]
  • 11. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6): 803-20[DOI][PubMed]
  • 12. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO classification of tumours of the central nervous system. World Health Organization classification of tumours. 2007;
  • 13. Cohen AL, Holmen SL, Colman H. IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep. 2013; 13(5): 345[DOI][PubMed]
  • 14. Chamberlain MC, Born D. Prognostic significance of relative 1p/19q codeletion in oligodendroglial tumors. J Neuro Oncol. 2015; 125(2): 249-51
  • 15. Ellison DW, Kocak M, Figarella-Branger D, Felice G, Catherine G, Pietsch T, et al. Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. J Negat Results Biomed. 2011; 10: 7[DOI][PubMed]
  • 16. Pant I, Chaturvedi S, Jha DK, Kumari R, Parteki S. Central nervous system tumors: Radiologic pathologic correlation and diagnostic approach. J Neurosci Rural Pract. 2015; 6(2): 191-7[DOI][PubMed]
  • 17. Iwama T, Yamada H, Sakai N, Andoh T, Nakashima T, Hirata T, et al. Correlation between magnetic resonance imaging and histopathology of intracranial glioma. Neurol Res. 1991; 13(1): 48-54[PubMed]
  • 18. Horbinski C, Miller CR, Perry A. Gone FISHing: clinical lessons learned in brain tumor molecular diagnostics over the last decade. Brain Pathol. 2011; 21(1): 57-73[DOI][PubMed]
  • 19. Goyal N, Kakkar A, Sarkar C, Agrawal D. Does bony hyperostosis in intracranial meningioma signify tumor invasion? A radio-pathologic study. Neurol India. 2012; 60(1): 50-4[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader